哮喘患者使用度普利尤单抗与其他生物制剂相比的淋巴瘤风险:回顾性队列研究
该回顾性队列研究基于TriNetX全球联邦健康研究网络,纳入2015至2025年间启动度普利尤单抗、奥马珠单抗、美泊利单抗或贝那利珠单抗治疗的成人哮喘患者,经倾向评分匹配后比较淋巴瘤发病率。结果显示,度普利尤单抗与其他生物制剂相比,淋巴瘤发生率无统计学显著差异,乳腺癌、肺癌和前列腺癌亦无显著差异。
要点
- 度普利尤单抗与奥马珠单抗相比,淋巴瘤发生率无显著差异(HR 1.25,95%CI 0.78-2.00)。
- 度普利尤单抗与美泊利单抗、贝那利珠单抗相比,淋巴瘤发生率亦无显著差异。
- 乳腺癌、肺癌和前列腺癌发生率在组间均无显著差异。
核心结论
- 度普利尤单抗与其他哮喘生物制剂相比,淋巴瘤发生率无统计学显著差异,随访期最长5年。
研究设计与样本
- 回顾性队列研究,使用TriNetX全球联邦健康研究网络,纳入2015至2025年启动度普利尤单抗、奥马珠单抗、美泊利单抗或贝那利珠单抗治疗的成人哮喘患者,经倾向评分匹配平衡基线特征。
- 匹配后度普利尤单抗组10841例,奥马珠单抗组10841例,美泊利单抗组8088例,贝那利珠单抗组7330例。
主要发现
- 随访最长5年,淋巴瘤每1000人年发病率:度普利尤单抗vs奥马珠单抗为1.5 vs 0.8(HR 1.25;95%CI 0.78-2.00)。
- 度普利尤单抗vs美泊利单抗淋巴瘤发病率为1.5 vs 1.5(HR 0.91;95%CI 0.53-1.56)。
- 度普利尤单抗vs贝那利珠单抗淋巴瘤发病率为1.5 vs 1.7(HR 0.84;95%CI 0.47-1.51)。
- 乳腺癌、肺癌和前列腺癌发生率在各组间均无显著差异。
临床怎么用
- 对于使用度普利尤单抗治疗的重度哮喘患者,最长5年随访数据未显示淋巴瘤风险较其他生物制剂显著增加,可为临床用药咨询提供参考。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Dupilumab, an IL-4 receptor α antagonist, has transformed the treatment of severe asthma, but has been linked to reports of lymphoma, particularly cutaneous T-cell lymphoma. Whether lymphoma risk differs between dupilumab and other asthma biologics remains unclear. RESEARCH QUESTION: What is the comparative incidence of lymphoma among adult patients with asthma treated with dupilumab vs omalizumab, mepolizumab, or benralizumab? STUDY DESIGN AND METHODS: We conducted a retrospective cohort study using the TriNetX global federated health research network. Adults with asthma initiating dupilumab, omalizumab, mepolizumab, or benralizumab treatment between 2015 and 2025 were identified. Propensity score matching balanced baseline demographic and clinical characteristics. The primary outcome was lymphoma incidence. Secondary outcomes included lung, breast, and prostate cancers. Hazard ratios (HRs) with 95% CIs were estimated using Cox proportional hazards models. RESULTS: After matching, 10,841 patients receiving dupilumab were compared with 10,841 patients receiving omalizumab, 8,088 patients receiving mepolizumab, and 7,330 patients receiving benralizumab. Over up to 5 years of follow-up, lymphoma incidence rates per 1,000 person-years were 1.5 vs 0.8 (HR, 1.25; 95% CI, 0.78-2.00) for dupilumab vs omalizumab, 1.5 vs 1.5 (HR, 0.91; 95% CI, 0.53-1.56) vs mepolizumab, and 1.5 vs 1.7 (HR, 0.84; 95% CI, 0.47-1.51) vs benralizumab. No significant differences were observed for breast, lung, or prostate cancer. INTERPRETATION: Our results show that no statistically significant differences in lymphoma incidence were observed between dupilumab and other biologics. These findings provide comparative reassurance regarding lymphoma risk with dupilumab over up to 5 years of follow-up.
引用
- Liao KM, Huang SC, Kuo CY, et al. Risk of Lymphoma in Patients With Asthma Treated With Dupilumab Compared With Other Biologic Agents: A Retrospective Cohort Study. Chest. 2026. PMID: 42521147. doi:10.1016/j.chest.2026.07.5213
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。